CVE:HLSHLS Therapeutics Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding HLS Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume49,300 shsAverage Volume97,793 shsMarket CapitalizationC$384.86 millionP/E RatioN/ADividend Yield1.46%BetaN/A ProfileAnalyst RatingsEarningsHeadlinesSocial Media HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and distributes pharmaceutical products in North American markets. It is focused on treatment products for the central nervous system and cardiovascular specialties. The company was incorporated in 2014 and is headquartered in Toronto, Canada.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for HLS Therapeutics. Previous Next 2.6 Community Rank Outperform VotesHLS Therapeutics has received 56 “outperform” votes. (Add your “outperform” vote.)Underperform VotesHLS Therapeutics has received 53 “underperform” votes. (Add your “underperform” vote.)Community SentimentHLS Therapeutics has received 51.38% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about HLS Therapeutics and other stocks. Vote “Outperform” if you believe HLS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HLS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldHLS Therapeutics has a dividend yield of 1.46%, which is in the bottom 25% of all stocks that pay dividends.Dividend GrowthHLS Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, HLS Therapeutics insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for HLS Therapeutics are expected to decrease by -100.00% in the coming year, from C$0.04 to C$0.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of HLS Therapeutics is -14.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of HLS Therapeutics is -14.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.52 out of 5 stars Industry, Sector and Symbol Stock Exchange CVE Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolCVE:HLS Previous Symbol CUSIPN/A CIKN/A Webwww.hlstherapeutics.com Phone647-495-9000Debt Debt-to-Equity Ratio60.11 Current Ratio0.84 Quick Ratio0.75Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesC$65.13 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow38.84 Book ValueC$6.11 per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares27,295,300Market CapC$384.86 million Next Earnings DateN/A OptionableNot Optionable Receive HLS News and Ratings via Email Sign-up to receive the latest news and ratings for HLS and its competitors with MarketBeat's FREE daily newsletter. HLS Therapeutics (CVE:HLS) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of HLS Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for HLS Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for HLS Therapeutics. Has HLS Therapeutics been receiving favorable news coverage? Headlines about HLS stock have been trending somewhat negative on Thursday, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. HLS Therapeutics earned a coverage optimism score of -1.6 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near future. View the latest news about HLS Therapeutics. Who are some of HLS Therapeutics' key competitors? Some companies that are related to HLS Therapeutics include Knight Therapeutics (GUD), Ecofibre (EOF), Hexo (HEXO), OrganiGram (OGI), HEXO (HEXO), Amryt Pharma (AMYT), Next Science (NXS), ICC Labs (ICC), Benchmark (BMK), ESSA Pharma (EPI), Green Organic Dutchman (TGOD), Probiotec (PBP), Shield Therapeutics (STX), cbdMD (YCBD) and Althea Group (AGH). View all competitors. What other stocks do shareholders of HLS Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other HLS Therapeutics investors own include Allena Pharmaceuticals (ALNA), AcelRx Pharmaceuticals (ACRX), Ampliphi Biosciences (APHB), ProMetic Life Sciences (PLI), Ritter Pharmaceuticals (RTTR), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), Aldeyra Therapeutics (ALDX), Ampio Pharmaceuticals (AMPE) and Apellis Pharmaceuticals (APLS). Who are HLS Therapeutics' key executives? HLS Therapeutics' management team includes the following people: Mr. William M. Wells M.B.A., B.A., MBA, Co-Founder & Exec. Chairman (Age 57)Mr. Gregory David Gubitz L.L.B., B.A., LL.B, Co-Founder, CEO & Director (Age 61)Mr. Gilbert Godin, Pres & COO (Age 59)Mr. Tim Hendrickson M.B.A., Chief Financial Officer (Age 47)Mr. Joseph Anthony MacLean B. Com., LL.B, Director of Corp. Devel. (Age 50) What is HLS Therapeutics' stock symbol? HLS Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "HLS." How big of a company is HLS Therapeutics? HLS Therapeutics has a market capitalization of C$0.00 and generates C$65.13 million in revenue each year. What is HLS Therapeutics' official website? The official website for HLS Therapeutics is www.hlstherapeutics.com. How can I contact HLS Therapeutics? The company can be reached via phone at 647-495-9000. This page was last updated on 7/9/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
